BioLineRx Ltd.
BLRX
$3.22
$0.21797.26%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 502.92% | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 502.92% | -- | -- | -- | -- |
| Cost of Revenue | 150.89% | -- | -- | -- | -- |
| Gross Profit | 1,675.90% | -- | -- | -- | -- |
| SG&A Expenses | -6.02% | 22.13% | 78.52% | 126.73% | 173.94% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 0.63% | 26.08% | 51.44% | 58.49% | 63.91% |
| Operating Income | 55.45% | 29.55% | -1.66% | -21.99% | -47.45% |
| Income Before Tax | 84.79% | 62.03% | 30.42% | -52.71% | -142.93% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 84.79% | 62.03% | 30.42% | -52.71% | -142.93% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 84.79% | 62.03% | 30.42% | -52.71% | -142.93% |
| EBIT | 55.45% | 29.55% | -1.66% | -21.99% | -47.45% |
| EBITDA | 62.32% | 35.37% | 2.62% | -18.59% | -46.18% |
| EPS Basic | 88.17% | 68.25% | 37.78% | -30.26% | -93.88% |
| Normalized Basic EPS | 88.83% | 79.44% | 50.49% | -14.75% | -74.63% |
| EPS Diluted | 88.17% | 68.25% | 37.78% | -30.26% | -93.88% |
| Normalized Diluted EPS | 88.83% | 79.44% | 50.49% | -14.75% | -74.63% |
| Average Basic Shares Outstanding | 24.35% | 23.32% | 22.23% | 21.60% | 24.48% |
| Average Diluted Shares Outstanding | 24.35% | 23.32% | 22.23% | 21.60% | 24.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |